Randomised, Double-blind, Placebo-controlled and Parallel Group Trial to Investigate the Effects of One Dose (Up-titration to a Fixed Dose Regimen) of Oral BI 685509 on Portal Hypertension After 8 Weeks Treatment in Patients With Clinically Significant Portal Hypertension (CSPH) in Decompensated Cirrhosis After Their First Decompensation Event, Who Are Stabilized CTP 5-7
Latest Information Update: 14 Jun 2025
At a glance
- Drugs Avenciguat (Primary)
- Indications Portal hypertension
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 12 Jun 2024 Status changed from active, no longer recruiting to discontinued. (Reason the study was stopped: Company decision)
- 15 May 2024 Planned End Date changed from 12 Aug 2024 to 31 May 2024.
- 15 May 2024 Planned primary completion date changed from 29 Jul 2024 to 31 May 2024.